Edward van Wezel
Presidente presso Biogeneration Management BV
Profilo
Edward C.
M.
van Wezel is currently a Director at SynAffix BV, Confo Therapeutics NV, Escalier Biosciences BV, Scenic Biotech BV, and TigaTx, Inc. He is also a Managing Partner at Biogeneration Management BV since 2009.
In addition, he holds positions as an Investment Manager at Stichting Publieke Private Samenwerking Versterking, and as a Member-Supervisory Board at Genase Therapeutics BV and TigaTx BV.
Previously, Mr. van Wezel served as the Chief Executive Officer of Macrozyme BV, Director-Supervisory Board of Polpharma Biologics Utrecht BV, Director of dualyx NV, Principal at Janssen Pharmaceuticals, Inc., and Principal at CHIRON Biopharmaceuticals.
He also held positions as a Member-Supervisory Board at Progentix Orthobiology BV, NovioGendix Holding BV, Arcarios BV, and Cristal Delivery BV.
Mr. van Wezel graduated from Delft University of Technology and the University of Utrecht.
Posizioni attive di Edward van Wezel
Società | Posizione | Inizio |
---|---|---|
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Presidente | 01/01/2006 |
Stichting Publieke Private Samenwerking Versterking
Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Corporate Officer/Principal | 24/06/2011 |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Direttore/Membro del Consiglio | - |
Escalier Biosciences BV
Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Direttore/Membro del Consiglio | - |
Genase Therapeutics BV
Genase Therapeutics BV Pharmaceuticals: MajorHealth Technology Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands. | Direttore/Membro del Consiglio | - |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Direttore/Membro del Consiglio | - |
TigaTx BV
TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that specializes in research and development in the field of health nutrition. The company is based in Utrecht, Netherlands and was founded in 2020 by Jeanette Leusen. | Direttore/Membro del Consiglio | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Direttore/Membro del Consiglio | - |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Edward van Wezel
Società | Posizione | Fine |
---|---|---|
░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
Formazione di Edward van Wezel
University of Utrecht | Graduate Degree |
Delft University of Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 18 |
---|---|
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Finance |
Stichting Publieke Private Samenwerking Versterking
Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Miscellaneous |
CHIRON Biopharmaceuticals | |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Polpharma Biologics Utrecht BV
Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Commercial Services |
NovioGendix Holding BV
NovioGendix Holding BV Medical/Nursing ServicesHealth Services NovioGendix Holding BV provided molecular diagnostics services. The company was founded in 2006 by Willem J. G. Melchers, Jack A. Schalken and Rob Tweehuysen and was headquartered in Nijmegen, the Netherlands. | Health Services |
Arcarios BV
Arcarios BV Pharmaceuticals: MajorHealth Technology Arcarios BV discovers and develops innovative products for bone and joint diseases. The company is headquartered in Rotterdam, Netherlands. | Health Technology |
Macrozyme BV
Macrozyme BV Pharmaceuticals: MajorHealth Technology Macrozyme BV develops pharmaceutical compounds and technologies useful for the diagnosis and treatment of inflammatory disorders, lysosomal storage diseases and diabetes. The company was founded by Hans Aerts in 2001 and is headquartered in Amsterdam, The Netherlands. | Health Technology |
Progentix Orthobiology BV
Progentix Orthobiology BV Medical SpecialtiesHealth Technology Progentix Orthobiology BV develops CuriOs (TM), a unique suite of osteoconductive material products for clinical application in bone regenerative surgery. The company was founded by Joost Dick de Bruijn and Clemens A. van Blitterswijk in 2007 and is headquartered in Bilthoven, the Netherlands. | Health Technology |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Health Technology |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
Escalier Biosciences BV
Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Health Technology |
Genase Therapeutics BV
Genase Therapeutics BV Pharmaceuticals: MajorHealth Technology Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands. | Health Technology |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Commercial Services |
TigaTx BV
TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that specializes in research and development in the field of health nutrition. The company is based in Utrecht, Netherlands and was founded in 2020 by Jeanette Leusen. | Commercial Services |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Commercial Services |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Health Technology |
- Borsa valori
- Insiders
- Edward van Wezel